An Arkansas resident recently filed a Benicar lawsuit against pharmaceutical company Daiichi Sankyo, alleging that its blood pressure drugs like Benicar caused serious complications.

Plaintiff, Vickie G. used various blood pressure drugs from Daiichi Sankyo, including Benicar, Benicar HCT, and Tribenzor.

Vickie claims that these blood pressure drugs resulted in a series of complications, including chronic diarrhea, nausea, vomiting, weight loss, and other intestinal disease complications.

According to the Benicar lawsuit, these many problems resulted in pain and suffering, as well as unexpected financial expenses.

Vickie’s Benicar lawsuit claimed that she experienced these numerous Benicar side effects as a direct result of taking Benicar and these other blood pressure drugs.

She filed her blood pressure drugs lawsuit on multiple counts, including design defect, failure to warn, negligence and fraud, along with several others.

The Benicar lawsuit has, along with a number of others, been consolidated into a multidistrict litigation, or MDL.

Benicar lawsuits included in this multidistrict litigation allege that the pharmaceutical company Daiichi Sankyo either knew or should have known about the complications linked with their blood pressure drugs, yet failed to adequately warn the public and the medical community about these risks.

Had plaintiffs, like Vickie, been aware of these risks, they may have chosen to take a safer alternative to these blood pressure drugs, and avoided these Benicar side effects entirely.

Benicar Background

Benicar (olmesartan medoxomil) is manufactured by Daiichi Sankyo, Inc., and is popularly used for the treatment of hypertension. Benicar was first approved by the U.S. Food and Drug Administration in 2002.

Olmesartan medoxomil blood pressure drugs are marketed as Benicar, Benicar HCT, Tribenzor, and Azor. After their release onto the market, Benicar and other blood pressure drugs rose to popularity very quickly. Almost 2 million patients filled prescriptions for olmesartan blood pressure drugs in 2012 alone.

Side Effects of Blood Pressure Drugs

Since it was approved and released onto the market, Benicar has been linked with a series of complications in complaints through the FDA as well as lawsuits.

The U.S. Food and Drug Administration followed up these complaints on July 3, 2013, warning about Benicar’s association with medical problems like chronic diarrhea and weight gain.

The FDA also approved a change in the label of Benicar and the other olmesartan blood pressure drugs that would give adequate warning about these side effects.

Benicar Lawsuits

Despite these label changes, many lawsuits allege that Daiichi Sankyo has continued to market their Benicar products in the same manner that they did prior to the FDA’s official warning.

Lawsuits allege that the company is choosing to actively mislead both their customers and the medical community about the safety and efficacy of Benicar and other olmesartan blood pressure drugs.

If you or someone you love has experienced any of these or other Benicar side effects after taking olmesartan blood pressure drugs, you may be able to file a Benicar lawsuit against Daiichi Sankyo.

The Benicar Lawsuit is Case No. Case No. 1:16-cv-02971 and is part of the larger Benicar MDL No. 2606, in the U.S. District Court for the Camden Vicinage of the District of New Jersey.